<DOC>
	<DOCNO>NCT00202345</DOCNO>
	<brief_summary>One complication late stage kidney disease development low red blood cell count ( anaemia/low haemoglobin concentration ) . The Australian Commonwealth government limit fund medication ( call erythropoietic stimulate agent ) patient already develop anaemia . There evidence support beneficial effect maintain high haemoglobin patient . Higher haemoglobin delay onset dialysis reduce development heart enlargement . However , administration erythropoietic stimulate agent without risk , include high financial burden , worsen high blood pressure rare complication call pure red cell aplasia . Previous study show patient chronic kidney disease require additional iron maintain production red blood cell . Thus would timely determine administration iron sucrose patient maintain near normal haemoglobin concentration , without need start erythropoietic stimulating agent possibly delay dialysis . Study Hypothesis : That administration iron sucrose superior standard care prevention anaemia patient stage 3 /4 kidney disease .</brief_summary>
	<brief_title>Iron Sucrose Stage 3/4 Kidney Disease</brief_title>
	<detailed_description>Eligible patient approach . Those agree partake study , enrolment ( include inform consent ) , randomize one 2 group . Group A : To receive intravenous iron sucrose maintain supra-physiological measure iron status ) Group A target ferritin level 300 500µg/L and/or transferrin saturation 25 50 % . Between 100 200mg intravenous iron sucrose administer slow bolus injection one- two-monthly achieve level . Oral iron use routinely group . Group B : Will oral iron therapy require maintain ferritin level 100 150µg/L and/or transferrin saturation &gt; 20 % &lt; 25 % . Patients Group B unable tolerate oral iron administer iron sucrose necessary maintain acceptable iron level . Patients Group B therefore differ Group A ( ) routine use iron sucrose ( b ) maintenance different ferritin transferrin saturation level .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Initial Hb concentration ≥ 110g/L ( male female ) 2 . Calculated GFR ≤ 35mL/min ( ≤ 50mL/min diabetic ) 3 . Demonstration clinically significant rise creatinine and/or drop Hb concentration previous 18 month . If data available , investigator make decision regard eligibility base clinical circumstance . 1 . Age &gt; 80 2 . Pregnancy* 3 . Unstable ischaemic heart disease* 4 . Uncontrolled , severe , congestive cardiac failure 5 . Haemochromatosis iron overload* ( ferritin &gt; 300µg/L TSAT &gt; 25 % ) 6 . Liver failure 7 . Myelodysplastic syndrome monoclonal gammopathy 8 . Active malignancy gastrointestinal bleeding* 9 . Persistent sepsis* significant chronic inflammation ( CRP &gt; 25 ) * 10 . Iron deficiency* ( Ferritin &lt; 30ug/L Tsat &lt; 15 % ) haematinic disorder 11 . Active significant haemolysis* 12 . Previous organ transplantation 13 . Concurrent significant past ( &gt; 6 month ) immunosuppression 14 . Adult polycystic kidney disease 15 . Current use ESA 16 . On dialysis * : patient still consider eligible condition reverse treated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Creatinine Clearance</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Iron sucrose</keyword>
	<keyword>Oral iron therapy</keyword>
	<keyword>Ferritin</keyword>
	<keyword>Transferrin saturation</keyword>
	<keyword>Iron</keyword>
</DOC>